CYP3A4 and CYP3A5 mRNA expression in hypercholesterolemic individuals under hypolipemiant therapy (2010)
- Authors:
- USP affiliated authors: DOREA, EGIDIO LIMA - HU ; HIRATA, MARIO HIROYUKI - FCF ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: HU; FCF
- Subjects: HIPERCOLESTEROLEMIA; POLIMORFISMO
- Language: Inglês
- Imprenta:
- Source:
- Título: Brazilian Journal of Pharmaceutical Sciences
- ISSN: 1984-8250
- Volume/Número/Paginação/Ano: v. 46, suppl. 2, p. 44 res. FCF084, 2010
- Conference titles: Science and Pharmaceutical Technology Meeting of the Pharmaceutical Sciences Faculty of the University of São Paulo
-
ABNT
WILLRICH, Maria Alice Vieira et al. CYP3A4 and CYP3A5 mRNA expression in hypercholesterolemic individuals under hypolipemiant therapy. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Hospital Universitário, Universidade de São Paulo. . Acesso em: 12 fev. 2026. , 2010 -
APA
Willrich, M. A. V., Genvigir, F. D. V., Rodrigues, A. C., Arazi, S. S., Oliveira, R. de, Maureira, A. D. C., et al. (2010). CYP3A4 and CYP3A5 mRNA expression in hypercholesterolemic individuals under hypolipemiant therapy. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Hospital Universitário, Universidade de São Paulo. -
NLM
Willrich MAV, Genvigir FDV, Rodrigues AC, Arazi SS, Oliveira R de, Maureira ADC, Dórea EL, Bernik MMS, Hirata MH, Hirata RDC. CYP3A4 and CYP3A5 mRNA expression in hypercholesterolemic individuals under hypolipemiant therapy. Brazilian Journal of Pharmaceutical Sciences. 2010 ; 46 44 res. FCF084.[citado 2026 fev. 12 ] -
Vancouver
Willrich MAV, Genvigir FDV, Rodrigues AC, Arazi SS, Oliveira R de, Maureira ADC, Dórea EL, Bernik MMS, Hirata MH, Hirata RDC. CYP3A4 and CYP3A5 mRNA expression in hypercholesterolemic individuals under hypolipemiant therapy. Brazilian Journal of Pharmaceutical Sciences. 2010 ; 46 44 res. FCF084.[citado 2026 fev. 12 ] - Leptin receptor gene polymorphisms are associated with adiposity and metabolic alterations in Brazilian individuals
- Relationships among CYP3A4 and CYP3A5 haplotypes, mRNA expression, CYP3A activity and atorvastatin response in hypercholesterolemic individuals
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- The contribution of genetic polymorphisms in 60 candidate genes to variability in atorvastatin response
- CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia
- Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
- Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- Differentiation of african components of ancestry to stratify groups in a case-control study of a brazilian urban population
- Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
